Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Zimran A, et al. Among authors: hughes da. Am J Hematol. 2013 Mar;88(3):172-8. doi: 10.1002/ajh.23383. Epub 2013 Jan 22. Am J Hematol. 2013. PMID: 23339116 Free PMC article. Clinical Trial.
The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsić M, Granovsky-Grisaru S, Amato D, vom Dahl S. Zimran A, et al. Among authors: hughes da. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):264-88. doi: 10.1016/j.bcmd.2009.04.003. Epub 2009 Jun 6. Blood Cells Mol Dis. 2009. PMID: 19502088 Review.
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.
Hollak CE, Aerts JM, Belmatoug N, Bembi B, Bodamer O, Cappellini D, Collin-Histed T, Cox TM, Deegan P, Giraldo P, Hughes D, Lukina E, Manuel J, Michelakakis H, Di Rocco M, Vellodi A, Zimran A. Hollak CE, et al. Blood Cells Mol Dis. 2010 Mar-Apr;44(2):86-7. doi: 10.1016/j.bcmd.2009.12.002. Blood Cells Mol Dis. 2010. PMID: 20022271 No abstract available.
Early access experience with VPRIV(®): recommendations for 'core data' collection.
Hughes DA, Al-Sayed M, Belmatoug N, Bodamer O, Böttcher T, Cappellini M, Cohen IJ, Eagleton T, Elstein D, Giraldo P, Jones S, Kaplinsky C, Lund A, Machaczka M, Mengel E, Pastores GM, Rosenbaum H, Sjo M, Tiling N, Tsaftaridis P, Zimran A, Weinreb N. Hughes DA, et al. Blood Cells Mol Dis. 2011 Aug 15;47(2):140-2. doi: 10.1016/j.bcmd.2010.10.015. Epub 2010 Dec 13. Blood Cells Mol Dis. 2011. PMID: 21146428 No abstract available.
Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease.
Torralba-Cabeza MÁ, Olivera S, Hughes DA, Pastores GM, Mateo RN, Pérez-Calvo JI. Torralba-Cabeza MÁ, et al. Among authors: hughes da. Mol Genet Metab. 2011 Nov;104(3):301-7. doi: 10.1016/j.ymgme.2011.06.021. Epub 2011 Jul 1. Mol Genet Metab. 2011. PMID: 21795086
The cognitive profile of type 1 Gaucher disease patients.
Biegstraaten M, Wesnes KA, Luzy C, Petakov M, Mrsic M, Niederau C, Giraldo P, Hughes D, Mehta A, Mengel KE, Hollak CE, Maródi L, van Schaik IN. Biegstraaten M, et al. J Inherit Metab Dis. 2012 Nov;35(6):1093-9. doi: 10.1007/s10545-012-9460-7. Epub 2012 Feb 21. J Inherit Metab Dis. 2012. PMID: 22350617 Free PMC article.
523 results